What are the effects of ranolazine on disease-specific health status and quality of life among patients with acute coronary syndromes?
The effects of ranolazine on disease-specific health status and quality of life among patients with acute coronary syndromes were evaluated in a randomized trial called the MERLIN-TIMI 36. The results of the trial showed that ranolazine was associated with improved disease-specific health status and quality of life. Specifically, it was associated with improved angina symptoms, physical functioning, general health perception, and quality of life scores compared to placebo. In addition, ranolazine was associated with a reduction in hospital readmissions due to cardiac-related symptoms. Overall, these results suggest that ranolazine may be beneficial in improving disease-specific health status and quality of life in patients with acute coronary syndromes.  